← Back to Search

Brachytherapy

MRI-Guided Radiation Therapy for Prostate Cancer (MARS Trial)

Q: Are there vacancies available for individuals interested in participating in this experiment?

<p>According to the clinicaltrials.gov repository, this trial is no longer in need of patients. Initially posted on September 24th 2015 and last updated June 12th 2022, it has since been superseded by 1321 other active studies that are presently recruiting volunteers for medical research.</p>

N/A

Waitlist Available

Led By Andrew Loblaw, MD

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed diagnosis of adenocarcinoma of the prostate

Low and Intermediate risk disease defined as T1-T2c, Gleason < 7 and PSA < 20 ng/ml

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

MARS Trial Summary

This trial is testing whether a higher dose of radiation to the area of the prostate where the cancer is located is safe and effective.

Who is the study for?

This trial is for men with low to intermediate risk prostate cancer, characterized by specific clinical features (T1-T2c, Gleason score <7, PSA <20 ng/ml), a prostate size less than 60 cc, and no distant metastases. Participants must be able to undergo MRI scans and have not had certain previous treatments or conditions that would exclude them from MR imaging or radiotherapy.Check my eligibility

What is being tested?

The study is testing the safety and effectiveness of using high dose rate brachytherapy with an MRI-assisted focal boost on the whole gland in treating prostate cancer. The goal is to see if targeting higher radiation doses directly at the primary disease area can improve outcomes without increasing harm to surrounding tissues.See study design

What are the potential side effects?

Potential side effects may include urinary issues due to inflammation or damage from radiation, bowel complications like diarrhea or discomfort, erectile dysfunction as a result of nerve damage near the treatment area, and general fatigue commonly associated with radiation therapy.

MARS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My prostate cancer diagnosis was confirmed through a tissue examination.

Select...

My prostate cancer is in the early or intermediate stage.

Select...

My prostate is smaller than 60 cc according to imaging tests.

MARS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acute GU and GI toxicities

Secondary outcome measures

Changes in serum prostate-specific antigen (PSA)

Changes in urinary symptoms

Late GU and GI toxicities

+2 more

MARS Trial Design

1Treatment groups

Experimental Treatment

Group I: MRI assisted HDR monotherapyExperimental Treatment1 Intervention

HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor

657 Previous Clinical Trials

1,551,251 Total Patients Enrolled

34 Trials studying Prostate Cancer

12,578 Patients Enrolled for Prostate Cancer

Andrew Loblaw, MDPrincipal InvestigatorSunnybrook Health Sciences Centre

7 Previous Clinical Trials

480 Total Patients Enrolled

6 Trials studying Prostate Cancer

328 Patients Enrolled for Prostate Cancer

Media Library

MRI Assisted Focal Boost with HDR Monotherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02623933 — N/A

Prostate Cancer Research Study Groups: MRI assisted HDR monotherapy

Prostate Cancer Clinical Trial 2023: MRI Assisted Focal Boost with HDR Monotherapy Highlights & Side Effects. Trial Name: NCT02623933 — N/A

MRI Assisted Focal Boost with HDR Monotherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02623933 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available for individuals interested in participating in this experiment?

"According to the clinicaltrials.gov repository, this trial is no longer in need of patients. Initially posted on September 24th 2015 and last updated June 12th 2022, it has since been superseded by 1321 other active studies that are presently recruiting volunteers for medical research."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients

Andrew Loblaw 2015. "MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02623933.